Physician profile

Paul Abend

Physical Medicine & Rehabilitation · Metuchen, NJ

NPI 1922165349

$166.01

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$74.91
Education$17.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Curonix LLC $40.30 2023 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Spr Therapeutics, INC $36.81 2022-2023 Sprint Pns System
Medtronic, INC. $34.10 2021
Nevro Corp. $16.60 2023 Senza
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $13.49 2024 Trulance, Xifaxan
Amgen INC. $12.79 2022
Otsuka America Pharmaceutical, INC. $11.92 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul Abend

$166.01

in general payments reported 2019-2025

Years
2021-2024
Top company
Curonix LLC

https://glasscript.com/doctor/178377/paul-abend

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.